

Nixon & Vanderhye PC

ATTORNEY AT LAW

8TH FLOOR
1100 NORTH GLEBE ROAD
ARLINGTON, VIRGINIA 22201-4714

TELEPHONE: (703) 816-4000
FACSIMILE: (703) 816-4100
WRITER'S DIRECT DIAL NUMBER:
(703) 816-4011

FACSIMILE COVER SHEET
PLEASE DELIVER IMMEDIATELY!!!!

Atty Dkt.: 1579-321Date: August 18, 2003To: Examiner Unger, S. - Group: 1642Firm: USPTOFacsimile No.: (703) 746-3142From: Mary J. WilsonNumber of Pages (including cover sheet): 31

(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION,
PLEASE CONTACT US IMMEDIATELY AT (703-816-4000).

ATTACHMENT/S: COURTESY COPY OF INFORMATION DISCLOSURE
STATEMENT FILED AUGUST 15, 2003, WITH PTO 1449
FORM, REFERENCES AND POSTCARD RECEIPT

In re PATENT APPLICATION OF:

GARCIA-BLANCO et al

Serial No.: 09/465,802

Filed: December 17, 1999

For: ALTERNATIVE SPLICING OF FIBROBLAST GROWTH FACTOR
RECEPTOR 2 MRNA IN PROSTATE CANCER

Dear Examiner Unger:

The attached is per our discussion of this morning. Please note that the Carstens et al abstract (listed first on the attached PTO 1449 Form) was listed on the PTO 1449 Form filed October 7, 2002, however, we noted that that Form did not include the date (the Abstract and date are referenced on page 19 of the 116 Amendment filed August 12, 2002).

Regards.

Mary Wilson

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for return of the original documents to us.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Atty Dkt. 1579-321

C# M#

GARCIA-BLANCO et al

Group Art Unit: 1642

Serial No. 09/465,802

Examiner: Unger, S.

Filed: December 17, 1999

Date: August 15, 2003

Title: ALTERNATIVE SPLICING OF FIBROBLAST GROWTH FACTOR RECEPTOR 2
MRNA IN PROSTATE CANCERCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00

Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 84.00	\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$ 0.00
--	---------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)	\$ 0.00
--	---------

Terminal disclaimer enclosed, add \$ 110.00	\$ 0.00
---	---------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)	\$ 0.00
---	---------

☐ Please enter the previously unentered, filed
☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 180.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 180.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tatNIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955Signature: Mary J. Wilson

IDS #19
8.19.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GARCIA-BLANCO et al

Atty. Ref.: 1579-321
Confirmation No. 9348

Serial No. 09/465,802

Group: 1642

Filed: December 17, 1999

Examiner: Unger, S.

For: ALTERNATIVE SPLICING OF FIBROBLAST GROWTH
FACTOR RECEPTOR 2 MRNA IN PROSTATE CANCER

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 15, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. PTO-1449 Pursuant to 37 CFR 1.97(b)
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) Statement Pursuant to 37 CFR 1.97(e)
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) Fee Payment Pursuant to 37 CFR 1.97(e)
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. Pursuant to 37 CFR 1.97(d)
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of
each non-English language document (such as a Search Report) is

GARCIA-BLANCO et al
Serial No. 09/465,802
August 15, 2003

enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

GARCIA-BLANCO et al
Serial No. 09/465,802
August 15, 2003

Respectfully submitted,
NIXON & VANDERHYE P.C.

By:

Mary J. Wilson

Mary J. Wilson

Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100